Multiomics Market by Offerings [Product (Instrument, Kits, Reagents), Service], Method (Epigenomics, Single Cell, Spatial), Technology [Sequencing, Proteomics (NGS, PCR, MS)], Workflow (Sample Prep), Application, Competition - Global Forecast to 2031

icon1
USD 5.70 BN
MARKET SIZE, 2031
icon2
CAGR 12.3%
(2026-2031)
icon3
576
REPORT PAGES
icon4
976
MARKET TABLES

OVERVIEW

multiomics-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The global multiomics market is projected to reach USD 5.70 billion by 2031 from USD 3.18 billion in 2026, at a CAGR of 12.3%. The multiomics market encompasses the technologies, products, and services used to integrate and analyze multiple biological data layers, including genomics, transcriptomics, proteomics, epigenomics, and spatial omics. The market includes sequencing platforms, mass spectrometry systems, microarrays, single-cell and spatial analysis technologies, bioinformatics software, data analysis platforms, and associated consumables and services. It supports pharmaceutical and biotechnology companies, academic and research institutions, CROs/CDMOs, and healthcare organizations in applications such as drug discovery and development, biomarker identification, precision medicine, disease research, clinical research, and systems biology.

KEY TAKEAWAYS

  • BY REGION
    North America accounted for the largest market share of 44.2% in 2025.
  • BY OFFERINGS
    By offering, the products segment accounted for the largest market share of 43.4% in 2025.
  • BY METHOD
    By method, spatial omics is the fastest-growing segment, growing at a CAGR of 13.8% during the forecast period.
  • BY TECHNOLOGY
    By technology, sequencing accounted for the largest share of 37.5% in 2025 and is projected to register the highest CAGR of 13.2% during the forecast period.
  • BY END USER
    Pharmaceutical & biotechnology companies dominated the market, accounting for 44% of the market in 2025.
  • COMPETITIVE LANDSCAPE - Key Players
    10x Genomics, Thermo Fisher Scientific Inc., Illumina, Inc., and Oxford Nanopore Technologies plc were identified as some of the star players in the global multiomics market, given their strong market share and product and service footprint.
  • COMPETITIVE LANDSCAPE - Startups
    RayBiotech, Inc. (US) andAzenta, Inc, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.

The global multiomics market is expanding steadily, driven by the growing demand for integrated biological data analysis, increasing investments in precision medicine and biopharmaceutical research, and rising adoption of advanced multiomics technologies across drug discovery, biomarker research, clinical research, and translational applications.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The global multiomics market is expanding steadily, driven by growing demand for integrated biological data analysis, increasing investments in precision medicine and biopharmaceutical research, and rising adoption of genomics, transcriptomics, proteomics, epigenomics, and spatial omics technologies across drug discovery, biomarker identification, disease research, clinical research, and translational applications.

multiomics-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Rising use of multiomics in precision medicine and disease stratification
  • Rapid adoption of single-cell and spatial multiomics
RESTRAINTS
Impact
Level
  • Complexity of multiomics data integration and standardization
  • High multiomics costs constrain technology adoption
OPPORTUNITIES
Impact
Level
  • Growing adoption of spatial proteomics for tissue-context analysis and biomarker discovery
  • Increasing emergence of single-cell proteomics for high-resolution characterization of cellular profiles
CHALLENGES
Impact
Level
  • Lack of standardization across multiomics workflows

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Rising use of multiomics in precision medicine and disease stratification

Increasing adoption of multiomics in precision medicine and disease research is driving demand for integrated molecular profiling technologies that enable comprehensive disease characterization, biomarker discovery, patient stratification, and targeted treatment development.

Restraint: Complexity of multiomics data integration and standardization.

High computational requirements, complex data integration processes, diverse analytical platforms, and the need for specialized bioinformatics expertise continue to increase operational complexity and constrain the broader adoption of multiomics technologies.

Opportunity: Growing adoption of spatial proteomics for tissue-context analysis and biomarker discovery.

Emerging applications of spatial proteomics are creating new opportunities for high-resolution tissue analysis, biomarker discovery, disease characterization, and precision medicine by enabling molecular profiling while preserving spatial information.

Challenge: Lack of standardization across multiomics workflows

Scaling multiomics workflows across research and clinical applications remains challenging because of variations in sample preparation, assay technologies, data formats, analytical methods, and quality-control procedures, which can affect reproducibility and data comparability.

MULTIOMICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
 Provides Illumina Connected Multiomics, a cloud-based platform that integrates and analyzes genomics, transcriptomics, proteomics, epigenomics, and other multiomic datasets. For example, oncology researchers at the University of Colorado Anschutz Medical Campus used the platform to analyze proteomic data and generate insights into melanoma biology. Enables integrated analysis of multiple biological data layers, helping researchers identify biomarkers, understand disease mechanisms, and accelerate precision medicine and drug discovery. (Illumina)
company logo
 Provides Chromium Single Cell Multiome ATAC + Gene Expression technology, enabling simultaneous profiling of chromatin accessibility and gene expression in individual cells. Its platforms are widely used in cancer, immunology, and developmental biology research to characterize cellular states and regulatory mechanisms. Provides a comprehensive view of gene regulation at single-cell resolution, helping researchers link regulatory elements with gene expression and identify disease-associated cell populations.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The global multiomics market is a highly interconnected ecosystem in which pharmaceutical and biotechnology companies, academic institutions, research organizations, and healthcare providers collaborate to generate, integrate, and interpret data across genomics, transcriptomics, proteomics, metabolomics, epigenomics, and spatial omics. Technology providers offer advanced sequencing, mass spectrometry, single-cell, spatial analysis, and bioinformatics platforms, along with associated reagents, consumables, and data analysis solutions. Contract research organizations (CROs) and specialized service providers support sample processing, multiomic profiling, data integration, bioinformatics, and biomarker discovery across research and clinical development stages. Regulatory authorities and healthcare systems across regions such as North America and Europe establish evolving standards for data quality, clinical validation, privacy, and analytical reproducibility, driving innovation, interoperability, compliance, and the adoption of multiomics in precision medicine, drug discovery, disease research, and translational applications.

multiomics-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

multiomics-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Global Multiomics Market, by Offering

In 2025, products accounted for the largest share, supported by the widespread adoption of sequencing platforms, mass spectrometry systems, reagents, kits, and other consumables required for multiomic analysis.

Global Multiomics Market, by Method

Single-cell omics accounted for the largest share of the global multiomics market in 2025, driven by its ability to characterize genomic, transcriptomic, epigenomic, and proteomic profiles at cellular resolution.

Global Multiomics Market, by Workflow

Sequencing & analysis/sample characterization accounted for the largest share of the global multiomics market in 2025, supported by the growing use of sequencing and analytical workflows for generating comprehensive molecular profiles.

Global Multiomics Market, by Technology

Sequencing technologies accounted for the largest share of the global multiomics market in 2025, driven by advances in high-throughput, single-cell, long-read, and spatial sequencing technologies and their expanding applications in disease research, precision medicine, and drug discovery.

Global Multiomics Market, by Application

Oncology accounted for the largest share of the global multiomics market in 2025, supported by the increasing use of integrated molecular profiling to understand tumor heterogeneity, identify biomarkers, and guide precision treatment.

Global Multiomics Market, by End User

Pharmaceutical & biotechnology companies accounted for the largest share of the global multiomics market in 2025, driven by the increasing adoption of multiomic technologies for drug discovery, biomarker identification, precision medicine, and translational research.

REGION

Asia Pacific to be fastest-growing region in market during forecast period

During the forecast period, Asia Pacific is expected to witness rapid growth in the multiomics market, driven by increasing investments in genomics and precision medicine, expanding biotechnology and pharmaceutical research, and the growing adoption of advanced sequencing, single-cell, spatial omics, and bioinformatics technologies. The expansion of CRO services, research infrastructure, and healthcare applications further supports regional market growth.

multiomics-market Region

MULTIOMICS MARKET: COMPANY EVALUATION MATRIX

In the global multiomics market, 10x Genomics is the star player, driven by its strong portfolio of single-cell and spatial omics technologies, including solutions that enable integrated analysis of genomic, transcriptomic, epigenomic, and spatial data. The company maintains its leadership through continuous technological innovation, strong adoption across research and biopharmaceutical organizations, and strategic collaborations with academic and healthcare institutions. Biognosys is an emerging leader, supported by its advanced mass spectrometry-based proteomics and multiomics capabilities. The company's growing focus on high-throughput proteomic analysis, biomarker discovery, and data-driven biological insights positions it strongly to benefit from the rising demand for integrated multiomics research and precision medicine applications.

multiomics-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2025 (Value) USD 2.88 Billion
Market Size in 2026 (Value) USD 3.18 Billion
Market Forecast in 2031 (Value) USD 5.7 Billion
Growth Rate 12.3%
Years Considered 2024–2031
Base Year 2025
Forecast Period 2026–2031
Units Considered Value (USD Million/Billion)
Report Coverage Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends
Segments Covered
  • By Offering:
    • Products (Consumables
    • Instruments/Systems & Software)
    • Services
  • By Method:
    • Single-cell Omics (Single-cell Transcriptomics
    • Single-cell Epigenomics
    • Single-cell Proteomics
    • Single-cell Genomics
    • and Other Single-cell Omics)
    • Proteomics (NGS-based Proteomics
    • PCR-based Proteomics
    • Mass Spectrometry (MS)-based Proteomics
    • and Other Proteomics Methods)
    • Spatial Omics (Spatial Transcriptomics
    • Spatial Proteomics
    • Spatial Epigenomics
    • Spatial Genomics
    • and Other Spatial Omics)
    • Long-read & Long-range Sequencing (Long-read Sequencing
    • Long-range Sequencing
    • Other Methods)
    • Epigenomics (Sequencing-based Epigenomics [DNA Methylation Sequencing
    • Chromatin Accessibility Sequencing
    • Histone Modification Profiling
    • and Chromatin Interaction Analysis]
    • Other Epigenomics Methods)
    • and Other Methods
  • By Technology:
    • Sequencing (Long-read Sequencing [Nanopore Sequencing and Single-molecule Real-time (SMRT) Sequencing]
    • Other Sequencing Technologies)
    • Proteomics Technologies
    • Other Technologies
  • By Workflow:
    • Sample Preparation
    • Sequencing & Analysis/Sample Characterization
    • Data Visualization & Analysis
  • By Application:
    • Oncology
    • Cell Biology
    • Immunology
    • Neurology
    • Precision Medicine
    • Biomarker Discovery
    • Translational Research
    • Drug Discovery & Development
    • Clinical Diagnostics
    • Other Applications
  • By End User:
    • Pharmaceutical & Biotechnology Companies
    • Academic & Research Institutes
    • Hospital & Diagnostic/Clinical Laboratories
    • CROs & CDMOs
Regions Covered North America, Europe, Asia Pacific, Latin America, Middle East, Africa

WHAT IS IN IT FOR YOU: MULTIOMICS MARKET REPORT CONTENT GUIDE

multiomics-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Evaluate the competitive positioning of key players in the multiomics market Benchmarked leading companies across sequencing, single-cell, spatial omics, proteomics, metabolomics, bioinformatics, and integrated multiomics platforms based on technology capabilities, workflow coverage, product and service offerings, geographic reach, and end-user focus Identifies competitive gaps, technology differentiation opportunities, strategic partnerships, and market positioning strategies
Assess high-growth multiomics technologies and application opportunities Evaluated growth potential across genomics, transcriptomics, proteomics, metabolomics, epigenomics, single-cell multiomics, spatial omics, and AI-enabled data integration technologies Supports investment prioritization, technology development, product portfolio expansion, and service diversification strategies

RECENT DEVELOPMENTS

  • June 2026 : 10x Genomics acquired Proteintech Genomics to expand high-plex proteomics across its single-cell and spatial portfolios. The acquired Human Discovery Panel enables simultaneous measurement of intracellular and cell-surface proteins alongside transcriptomic information.
  • June 2026 : Thermo Fisher launched an integrated set of mass spectrometry and software solutions for multiomics, advanced proteomics, structural biology, biopharmaceutical characterization, and small-molecule analysis. The Orbitrap Tribrid Apex platform combines three mass analyzers with AI-enabled proteomics and proteoform-analysis software.

 

Table of Contents

checkmarkExclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
1
INTRODUCTION
 
 
 
 
 
53
2
EXECUTIVE SUMMARY
 
 
 
 
 
58
3
PREMIUM INSIGHTS
 
 
 
 
 
64
4
MARKET OVERVIEW
Precision medicine surges with multiomics, despite integration complexity and high costs.
 
 
 
 
 
67
 
4.1
INTRODUCTION
 
 
 
 
 
 
4.2
MARKET DYNAMICS
 
 
 
 
 
 
 
4.2.1
DRIVERS
 
 
 
 
 
 
 
4.2.1.1
RISING USE OF MULTIOMICS IN PRECISION MEDICINE AND DISEASE STRATIFICATION
 
 
 
 
 
 
4.2.1.2
RAPID ADOPTION OF SINGLE-CELL AND SPATIAL MULTIOMICS
 
 
 
 
 
 
4.2.1.3
INCREASING ACCESSIBILITY OF HIGH-QUALITY, INTEGRATED OMICS DATA FOR RESEARCH
 
 
 
 
 
 
4.2.1.4
AI, MACHINE LEARNING, AND CLOUD BIOINFORMATICS IMPROVING CROSS-OMICS INTERPRETATION
 
 
 
 
 
4.2.2
RESTRAINTS
 
 
 
 
 
 
 
4.2.2.1
COMPLEXITY OF MULTIOMICS DATA INTEGRATION AND STANDARDIZATION
 
 
 
 
 
 
4.2.2.2
HIGH COSTS CONSTRAIN TECHNOLOGY ADOPTION
 
 
 
 
 
4.2.3
OPPORTUNITIES
 
 
 
 
 
 
 
4.2.3.1
GROWING ADOPTION OF SPATIAL PROTEOMICS FOR TISSUE-CONTEXT ANALYSIS AND BIOMARKER DISCOVERY
 
 
 
 
 
 
4.2.3.2
INCREASING EMERGENCE OF SINGLE-CELL PROTEOMICS FOR HIGH-RESOLUTION CHARACTERIZATION OF CELLULAR PROFILES
 
 
 
 
 
4.2.4
CHALLENGES
 
 
 
 
 
 
 
4.2.4.1
LACK OF STANDARDIZATION ACROSS MULTIOMICS WORKFLOWS
 
 
 
 
4.3
UNMET NEEDS AND WHITE SPACES
 
 
 
 
 
 
4.4
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
 
 
 
 
 
 
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
 
 
 
 
 
5
INDUSTRY TRENDS
Navigate evolving industry dynamics with strategic insights from comprehensive multiomics and pricing trend analyses.
 
 
 
 
 
75
 
5.1
PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
 
5.1.1
THREAT OF NEW ENTRANTS
 
 
 
 
 
 
5.1.2
THREAT OF SUBSTITUTES
 
 
 
 
 
 
5.1.3
BARGAINING POWER OF BUYERS
 
 
 
 
 
 
5.1.4
BARGAINING POWER OF SUPPLIERS
 
 
 
 
 
 
5.1.5
INTENSITY OF COMPETITIVE RIVALRY
 
 
 
 
 
5.2
MACROECONOMIC OUTLOOK
 
 
 
 
 
 
 
5.2.1
INTRODUCTION
 
 
 
 
 
 
5.2.2
GDP TRENDS AND FORECAST
 
 
 
 
 
 
5.2.3
TRENDS IN GLOBAL HEALTHCARE INDUSTRY
 
 
 
 
 
 
5.2.4
TRENDS IN GLOBAL PHARMACEUTICAL INDUSTRY
 
 
 
 
 
5.3
VALUE CHAIN ANALYSIS
 
 
 
 
 
 
 
5.4
ECOSYSTEM ANALYSIS
 
 
 
 
 
 
 
5.5
PRICING ANALYSIS
 
 
 
 
 
 
 
 
5.5.1
AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY TYPE (2023–2025)
 
 
 
 
 
 
5.5.2
AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY TYPE, 2023–2025
 
 
 
 
 
 
5.5.3
AVERAGE SELLING PRICE TREND, BY REGION, 2023–2025
 
 
 
 
 
5.6
TRADE ANALYSIS
 
 
 
 
 
 
 
 
5.6.1
IMPORT DATA FOR HS CODE 9027
 
 
 
 
 
 
5.6.2
EXPORT DATA FOR HS CODE 9027
 
 
 
 
 
 
5.6.3
IMPORT VOLUME FOR HS CODE 9027
 
 
 
 
 
 
5.6.4
EXPORT VOLUME FOR HS CODE 9027
 
 
 
 
 
5.7
KEY CONFERENCES & EVENTS
 
 
 
 
 
 
5.8
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
 
 
5.9
INVESTMENT/FUNDING ACTIVITY
 
 
 
 
 
 
5.10
CASE STUDY ANALYSIS
 
 
 
 
 
 
 
5.10.1
ADVANCED MULTIOMICS PROFILING TO SUPPORT PRECISION MEDICINE ADOPTION
 
 
 
 
 
 
5.10.2
INTEGRATED LONG-READ SEQUENCING TO SUPPORT MULTIOMICS RESEARCH
 
 
 
 
 
 
5.10.3
MULTIOMICS DATA INTEGRATION TO ACCELERATE BIOMARKER DISCOVERY
 
 
 
 
 
5.11
IMPACT OF 2025 US TARIFFS—MULTIOMICS MARKET
 
 
 
 
 
 
 
 
5.11.1
INTRODUCTION
 
 
 
 
 
 
5.11.2
KEY TARIFF RATES
 
 
 
 
 
 
5.11.3
PRICE IMPACT ANALYSIS
 
 
 
 
 
 
5.11.4
IMPACT ON COUNTRIES/REGIONS
 
 
 
 
 
 
 
5.11.4.1
NORTH AMERICA
 
 
 
 
 
 
5.11.4.2
EUROPE
 
 
 
 
 
 
5.11.4.3
ASIA PACIFIC
 
 
 
 
 
5.11.5
IMPACT ON END-USE INDUSTRIES
 
 
 
 
 
 
 
5.11.5.1
PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
5.11.5.2
HOSPITALS AND DIAGNOSTIC LABORATORIES
 
 
 
 
 
 
5.11.5.3
ACADEMIC & RESEARCH INSTITUTES
 
 
 
 
 
 
5.11.5.4
CROS & CDMOS
 
 
 
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
AI-driven multiomics innovations propel future-ready applications and reshape market dynamics.
 
 
 
 
 
98
 
6.1
KEY TECHNOLOGIES
 
 
 
 
 
 
 
6.1.1
SINGLE-CELL MULTIOMICS CO-ASSAYS AND SCALABLE BARCODING
 
 
 
 
 
 
6.1.2
SPATIAL MULTIOMICS AND SUBCELLULAR TISSUE MAPPING
 
 
 
 
 
 
6.1.3
HIGH-PLEX PROTEOGENOMICS AND NGS/PCR-BASED PROTEIN READOUTS
 
 
 
 
 
6.2
ADJACENT TECHNOLOGIES
 
 
 
 
 
 
 
6.2.1
MICROARRAYS AND HYBRIDIZATION-BASED PROFILING
 
 
 
 
 
 
6.2.2
DIGITAL PATHOLOGY AND ADVANCED SPATIAL IMAGING
 
 
 
 
 
6.3
COMPLEMENTARY TECHNOLOGIES
 
 
 
 
 
 
 
6.3.1
MICROFLUIDICS, CELL/NUCLEI CAPTURE, AND SAMPLE INDEXING
 
 
 
 
 
 
6.3.2
HIGH-RESOLUTION MASS SPECTROMETRY AND ION MOBILITY
 
 
 
 
 
6.4
TECHNOLOGY/PRODUCT ROADMAP
 
 
 
 
 
 
6.5
PATENT ANALYSIS
 
 
 
 
 
 
 
 
6.5.1
TOP APPLICANTS/OWNERS (COMPANIES) FOR MULTIOMICS PATENTS, 2015–2025
 
 
 
 
 
6.6
FUTURE APPLICATIONS
 
 
 
 
 
 
6.7
IMPACT OF AI/GEN AI ON MULTIOMICS MARKET
 
 
 
 
 
 
 
 
6.7.1
TOP USE CASES AND MARKET POTENTIAL
 
 
 
 
 
 
6.7.2
BEST PRACTICES IN AI-ENABLED MULTIOMICS WORKFLOWS
 
 
 
 
 
 
6.7.3
CASE STUDIES OF AI IMPLEMENTATION IN MULTIOMICS MARKET
 
 
 
 
 
 
6.7.4
INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS
 
 
 
 
 
 
6.7.5
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN MULTIOMICS MARKET
 
 
 
 
7
REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
Navigate global regulatory complexities to drive impactful sustainability initiatives and eco-certifications.
 
 
 
 
 
107
 
7.1
REGIONAL REGULATIONS AND COMPLIANCE
 
 
 
 
 
 
 
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
7.1.2
INDUSTRY STANDARDS
 
 
 
 
 
7.2
SUSTAINABILITY INITIATIVES
 
 
 
 
 
 
7.3
IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
 
 
 
 
 
 
7.4
CERTIFICATIONS, LABELING, AND ECO-STANDARDS
 
 
 
 
 
8
MULTIOMICS MARKET, BY OFFERING
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 45 Data Tables
 
 
 
 
 
113
 
8.1
INTRODUCTION
 
 
 
 
 
 
8.2
PRODUCTS
 
 
 
 
 
 
 
8.2.1
CONSUMABLES
 
 
 
 
 
 
 
8.2.1.1
INCREASING EXPERIMENT VOLUMES, HIGHER MULTIPLEXING, AND RECURRING REAGENT REQUIREMENTS SUPPORT GROWTH
 
 
 
 
 
 
8.2.1.2
ASSAY KITS & REAGENTS
 
 
 
 
 
 
 
 
8.2.1.2.1
RECURRING ASSAY CONSUMPTION, HIGHER MULTIPLEXING, AND IMPROVED LOW-INPUT PERFORMANCE DRIVE MARKET GROWTH
 
 
 
 
8.2.1.3
OTHER CONSUMABLES
 
 
 
 
 
8.2.2
INSTRUMENTS & SOFTWARE
 
 
 
 
 
 
 
8.2.2.1
INTEGRATED MULTIOMICS PLATFORMS, AUTOMATED WORKFLOWS, AND AI-ENABLED DATA INTERPRETATION STRENGTHEN DEMAND
 
 
 
 
8.3
SERVICES
 
 
 
 
 
 
 
8.3.1
RISING OUTSOURCING OF SPECIALIZED PROFILING AND INTERPRETATION TO DRIVE MARKET GROWTH
 
 
 
 
9
MULTIOMICS MARKET, BY TECHNOLOGY
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 52 Data Tables
 
 
 
 
 
132
 
9.1
INTRODUCTION
 
 
 
 
 
 
9.2
SEQUENCING
 
 
 
 
 
 
 
9.2.1
LONG-READ SEQUENCING
 
 
 
 
 
 
 
9.2.1.1
NANOPORE SEQUENCING
 
 
 
 
 
 
 
 
9.2.1.1.1
REAL-TIME NATIVE-MOLECULE ANALYSIS, SCALABLE PLATFORMS, AND INTEGRATED GENOMIC–EPIGENOMIC READOUTS ARE ACCELERATING NANOPORE SEQUENCING ADOPTION
 
 
 
 
9.2.1.2
SMRT SEQUENCING
 
 
 
 
 
 
 
 
9.2.1.2.1
HIGH-ACCURACY HIFI READS AND LOWER SEQUENCING COST TO EXPAND SMRT-BASED MULTIOMICS
 
 
 
9.2.2
OTHER SEQUENCING TECHNOLOGIES
 
 
 
 
 
9.3
PROTEOMICS
 
 
 
 
 
 
 
9.3.1
ADVANCES IN HIGH-SENSITIVITY MASS SPECTROMETRY, SINGLE-CELL ANALYSIS, AND SCALABLE PROTEIN QUANTIFICATION ARE ACCELERATING PROTEOMICS ADOPTION IN MULTIOMICS RESEARCH
 
 
 
 
 
9.4
OTHER TECHNOLOGIES
 
 
 
 
 
10
MULTIOMICS MARKET, BY METHOD
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 210 Data Tables
 
 
 
 
 
154
 
10.1
INTRODUCTION
 
 
 
 
 
 
10.2
SINGLE-CELL OMICS
 
 
 
 
 
 
 
10.2.1
IMPROVED CELL CAPTURE AND GROWING DEMAND TO RESOLVE CELLULAR HETEROGENEITY DRIVE MARKET GROWTH
 
 
 
 
 
 
10.2.2
SINGLE-CELL TRANSCRIPTOMICS
 
 
 
 
 
 
 
10.2.2.1
HIGHER SAMPLE THROUGHPUT, IMPROVED CELL RECOVERY, AND COMPATIBILITY WITH FIXED CLINICAL SAMPLES ARE EXPANDING SINGLE-CELL TRANSCRIPTOMICS
 
 
 
 
 
10.2.3
SINGLE-CELL EPIGENOMICS
 
 
 
 
 
 
 
10.2.3.1
GROWING INTEREST IN GENE REGULATION, CHROMATIN STATE, AND TREATMENT RESISTANCE IS ACCELERATING SINGLE-CELL EPIGENOMICS RESEARCH
 
 
 
 
 
10.2.4
SINGLE-CELL PROTEOMICS
 
 
 
 
 
 
 
10.2.4.1
ULTRASENSITIVE MASS SPECTROMETRY AND HIGHER-THROUGHPUT PROTEIN QUANTIFICATION EXPANDING FUNCTIONAL ANALYSIS AT SINGLE-CELL RESOLUTION
 
 
 
 
 
10.2.5
SINGLE-CELL GENOMICS
 
 
 
 
 
 
 
10.2.5.1
IMPROVED DETECTION OF CLONAL VARIATION AND SIMULTANEOUS GENOTYPE-PHENOTYPE ANALYSIS ARE DRIVING SINGLE-CELL GENOMICS ADOPTION
 
 
 
 
 
10.2.6
OTHER SINGLE-CELL OMICS
 
 
 
 
 
10.3
PROTEOMICS
 
 
 
 
 
 
 
10.3.1
MS-BASED PROTEOMICS
 
 
 
 
 
 
 
10.3.1.1
DATA-INDEPENDENT ACQUISITION AND IMPROVED QUANTITATIVE DEPTH TO SUSTAIN MS-BASED PROTEOMICS LEADERSHIP
 
 
 
 
 
10.3.2
NGS-BASED PROTEOMICS
 
 
 
 
 
 
 
10.3.2.1
SEQUENCING READOUTS AND ULTRA-HIGH-PLEX PANELS TO MAKE NGS-BASED PROTEOMICS THE FASTEST-GROWING PROTEOMICS METHOD
 
 
 
 
 
10.3.3
PCR-BASED PROTEOMICS
 
 
 
 
 
 
 
10.3.3.1
SENSITIVE PROXIMITY-AMPLIFICATION ASSAYS TO SUPPORT TARGETED, LOW-VOLUME PROTEIN PROFILING
 
 
 
 
 
10.3.4
OTHER PROTEOMICS METHODS
 
 
 
 
 
10.4
SPATIAL OMICS
 
 
 
 
 
 
 
10.4.1
SPATIAL TRANSCRIPTOMICS
 
 
 
 
 
 
 
10.4.1.1
WHOLE-TRANSCRIPTOME TISSUE MAPPING AND HIGHER RESOLUTION TO SUSTAIN SPATIAL TRANSCRIPTOMICS LEADERSHIP
 
 
 
 
 
10.4.2
SPATIAL PROTEOMICS
 
 
 
 
 
 
 
10.4.2.1
HIGHER-PLEX IMAGING AND TISSUE PHENOTYPING TO ACCELERATE SPATIAL PROTEOMICS ADOPTION
 
 
 
 
 
10.4.3
SPATIAL EPIGENOMICS
 
 
 
 
 
 
 
10.4.3.1
MAPPING REGULATORY STATES WITHIN TISSUE TO EXPAND SPATIAL EPIGENOMICS FROM EARLY RESEARCH APPLICATIONS
 
 
 
 
 
10.4.4
SPATIAL GENOMICS
 
 
 
 
 
 
 
10.4.4.1
IN SITU VARIANT AND COPY-NUMBER MAPPING TO SUPPORT SPATIAL GENOMICS GROWTH
 
 
 
 
 
10.4.5
OTHER SPATIAL OMICS
 
 
 
 
 
10.5
LONG-READ & LONG-RANGE SEQUENCING
 
 
 
 
 
 
 
10.5.1
IMPROVED STRUCTURAL VARIANT, ISOFORM, AND NATIVE EPIGENETIC RESOLUTION TO ACCELERATE ADOPTION
 
 
 
 
 
 
10.5.2
LONG-READ SEQUENCING
 
 
 
 
 
 
 
10.5.2.1
HIGHER ACCURACY AND THROUGHPUT TO ENSURE MARKET LEADERSHIP
 
 
 
 
 
10.5.3
LONG-RANGE SEQUENCING
 
 
 
 
 
 
 
10.5.3.1
GENOME MAPPING AND LINKED INFORMATION TO IMPROVE STRUCTURAL AND HAPLOTYPE CHARACTERIZATION
 
 
 
 
 
10.5.4
OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS
 
 
 
 
 
10.6
EPIGENOMICS
 
 
 
 
 
 
 
10.6.1
SEQUENCING-BASED EPIGENOMICS
 
 
 
 
 
 
 
10.6.1.1
DNA METHYLATION SEQUENCING
 
 
 
 
 
 
 
 
10.6.1.1.1
GENOME-WIDE AND TARGETED METHYLATION ANALYSIS TO SUSTAIN THE LARGEST SEQUENCING-BASED EPIGENOMICS SHARE
 
 
 
 
10.6.1.2
CHROMATIN ACCESSIBILITY SEQUENCING
 
 
 
 
 
 
 
 
10.6.1.2.1
ATAC-SEQ ADOPTION AND REGULATORY ELEMENT MAPPING TO MAKE ACCESSIBILITY PROFILING THE FASTEST-GROWING EPIGENOMICS METHOD
 
 
 
 
10.6.1.3
HISTONE MODIFICATION PROFILING
 
 
 
 
 
 
 
 
10.6.1.3.1
LOWER-INPUT CHROMATIN PROFILING TO BROADEN ANALYSIS OF HISTONE-ASSOCIATED REGULATORY STATES
 
 
 
 
10.6.1.4
CHROMATIN INTERACTION ANALYSIS
 
 
 
 
 
 
 
 
10.6.1.4.1
3D GENOME MAPPING TO CONNECT DISTAL REGULATORY ELEMENTS WITH GENE ACTIVITY
 
 
 
10.6.2
OTHER EPIGENOMICS METHODS
 
 
 
 
 
10.7
OTHER METHODS
 
 
 
 
 
11
MULTIOMICS MARKET, BY WORKFLOW
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 22 Data Tables
 
 
 
 
 
237
 
11.1
INTRODUCTION
 
 
 
 
 
 
11.2
SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION
 
 
 
 
 
 
 
11.2.1
HIGHER-THROUGHPUT MOLECULAR PROFILING AND INCREASINGLY SENSITIVE ANALYTICAL PLATFORMS TO STRENGTHEN SEQUENCING AND SAMPLE CHARACTERIZATION WORKFLOWS
 
 
 
 
 
11.3
SAMPLE PREPARATION
 
 
 
 
 
 
 
11.3.1
IMPROVED SAMPLE PRESERVATION, CELL CAPTURE, AUTOMATION, AND MULTIPLEXING TO EXPAND SCALE AND REPRODUCIBILITY OF MULTIOMICS STUDIES
 
 
 
 
 
11.4
DATA VISUALIZATION & ANALYSIS
 
 
 
 
 
 
 
11.4.1
AI-ENABLED ANALYTICS AND MULTIMODAL INTEGRATION TO ACCELERATE CONVERSION OF COMPLEX MULTIOMICS DATA INTO BIOLOGICAL INSIGHTS
 
 
 
 
12
MULTIOMICS MARKET, BY APPLICATION
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 71 Data Tables
 
 
 
 
 
248
 
12.1
INTRODUCTION
 
 
 
 
 
 
12.2
ONCOLOGY
 
 
 
 
 
 
 
12.2.1
GROWING USE OF TUMOR MULTIOMICS FOR BIOMARKER DISCOVERY AND PATIENT STRATIFICATION DRIVES MARKET LEADERSHIP
 
 
 
 
 
12.3
DRUG DISCOVERY & DEVELOPMENT
 
 
 
 
 
 
 
12.3.1
DATA-DRIVEN TARGET SELECTION AND MECHANISM STUDIES TO MAKE DRUG DISCOVERY FASTEST-GROWING APPLICATION
 
 
 
 
 
12.4
IMMUNOLOGY
 
 
 
 
 
 
 
12.4.1
LARGE-SCALE IMMUNE PROFILING PROGRAMS TO ACCELERATE MULTIMODAL IMMUNOLOGY RESEARCH
 
 
 
 
 
12.5
PRECISION MEDICINE
 
 
 
 
 
 
 
12.5.1
INTEGRATED MOLECULAR AND CLINICAL DATA TO EXPAND PATIENT-SPECIFIC DECISION SUPPORT
 
 
 
 
 
12.6
BIOMARKER DISCOVERY
 
 
 
 
 
 
 
12.6.1
CROSS-OMICS VALIDATION TO IMPROVE BIOMARKER ROBUSTNESS AND CLINICAL RELEVANCE
 
 
 
 
 
12.7
CELL BIOLOGY
 
 
 
 
 
 
 
12.7.1
HIGHER-RESOLUTION PROFILING OF CELL STATES, INTERACTIONS, AND DIFFERENTIATION PROCESSES EXPANDING ROLE OF MULTIOMICS IN CELL BIOLOGY
 
 
 
 
 
12.8
TRANSLATIONAL RESEARCH
 
 
 
 
 
 
 
12.8.1
IMPROVED ANALYSIS OF SPECIMENS AND MORE SCALABLE SPATIAL WORKFLOWS ACCELERATE TRANSLATION OF MULTIOMICS DISCOVERIES INTO THERAPEUTIC RESEARCH
 
 
 
 
 
12.9
NEUROLOGY
 
 
 
 
 
 
 
12.9.1
BRAIN-CELL ATLASES AND SPATIALLY RESOLVED MOLECULAR PROFILING DRIVE UNDERSTANDING OF NEUROLOGICAL DISEASE PROGRESSION AND THERAPEUTIC TARGETS
 
 
 
 
 
12.10
CLINICAL DIAGNOSTICS
 
 
 
 
 
 
 
12.10.1
GROWING CLINICAL SEQUENCING INFRASTRUCTURE TO SUPPORT MULTIOMICS-RELATED DIAGNOSTIC ADOPTION
 
 
 
 
 
12.11
OTHER APPLICATIONS
 
 
 
 
 
13
MULTIOMICS MARKET, BY END USER
Market Size & Growth Rate Forecast Analysis to 2031 in USD Million | 29 Data Tables
 
 
 
 
 
277
 
13.1
INTRODUCTION
 
 
 
 
 
 
13.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
 
 
 
 
 
 
 
13.2.1
EXPANDING PRECISION MEDICINE INITIATIVES ACCELERATE MULTIOMICS ADOPTION
 
 
 
 
 
13.3
ACADEMIC & RESEARCH INSTITUTES
 
 
 
 
 
 
 
13.3.1
GROWING RESEARCH FUNDING DRIVING MULTIOMICS USAGE AMONG ACADEMIC AND RESEARCH INSTITUTES
 
 
 
 
 
13.4
CROS & CDMOS
 
 
 
 
 
 
 
13.4.1
OUTSOURCING OF COMPLEX PROFILING AND ANALYTICS TO MAKE CROS & CDMOS THE FASTEST-GROWING END USERS
 
 
 
 
 
13.5
HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES
 
 
 
 
 
 
 
13.5.1
CLINICAL EVIDENCE AND WORKFLOW STANDARDIZATION TO SUPPORT MEASURED ADOPTION IN HOSPITALS AND LABORATORIES
 
 
 
 
14
MULTIOMICS MARKET, BY REGION
Comprehensive coverage of 7 Regions with country-level deep-dive of 15 Countries | 439 Data Tables.
 
 
 
 
 
290
 
14.1
INTRODUCTION
 
 
 
 
 
 
14.2
NORTH AMERICA
 
 
 
 
 
 
 
14.2.1
US
 
 
 
 
 
 
 
14.2.1.1
REGULATORY ACCEPTANCE, CLINICALLY INTEGRATED MOLECULAR TESTING, AND POPULATION-SCALE HEALTH DATASETS ACCELERATE MULTIOMICS ADOPTION
 
 
 
 
 
14.2.2
CANADA
 
 
 
 
 
 
 
14.2.2.1
POPULATION-SCALE PRECISION HEALTH INITIATIVES EXPAND INTEGRATION CAPACITY
 
 
 
 
14.3
EUROPE
 
 
 
 
 
 
 
14.3.1
GERMANY
 
 
 
 
 
 
 
14.3.1.1
CLINICAL INTEGRATION OF GENOME SEQUENCING AND STRONG TRANSLATIONAL RESEARCH NETWORKS DRIVE MARKET GROWTH
 
 
 
 
 
14.3.2
UK
 
 
 
 
 
 
 
14.3.2.1
POPULATION-SCALE MULTIMODAL DATASETS, NHS INTEGRATION, AND INDUSTRY-BACKED BIOMARKER PROGRAMS PROPEL MARKET GROWTH
 
 
 
 
 
14.3.3
FRANCE
 
 
 
 
 
 
 
14.3.3.1
STANDARDIZED PRECISION-MEDICINE PATHWAYS AND STRONG ONCOLOGY RESEARCH NETWORKS DRIVE MARKET
 
 
 
 
 
14.3.4
ITALY
 
 
 
 
 
 
 
14.3.4.1
SHARED RESEARCH INFRASTRUCTURE WIDENING ACCESS BEYOND LEADING ACADEMIC CENTERS
 
 
 
 
 
14.3.5
SPAIN
 
 
 
 
 
 
 
14.3.5.1
HOSPITAL-LINKED GENOMICS PROGRAMS SUPPORT STEADY ADOPTION OF INTEGRATED PROFILING
 
 
 
 
 
14.3.6
REST OF EUROPE
 
 
 
 
 
14.4
ASIA PACIFIC
 
 
 
 
 
 
 
14.4.1
CHINA
 
 
 
 
 
 
 
14.4.1.1
LARGE-SCALE GENOMIC INITIATIVES AND RAPID ADOPTION OF PRECISION MEDICINE TECHNOLOGIES DRIVE GROWTH
 
 
 
 
 
14.4.2
JAPAN
 
 
 
 
 
 
 
14.4.2.1
MATURE BIOBANKS AND PHARMACEUTICAL RESEARCH SUPPORT STABLE, HIGH-VALUE ADOPTION
 
 
 
 
 
14.4.3
SOUTH KOREA
 
 
 
 
 
 
 
14.4.3.1
NATIONAL BIO-DATA INFRASTRUCTURE AND DIGITAL-HEALTH CAPABILITIES ACCELERATE MULTIOMICS USE
 
 
 
 
 
14.4.4
INDIA
 
 
 
 
 
 
 
14.4.4.1
GENOMEINDIA AND EXPANDING TRANSLATIONAL CAPACITY PROPEL RAPID GROWTH IN INDIAN MULTIOMICS MARKET
 
 
 
 
 
14.4.5
AUSTRALIA
 
 
 
 
 
 
 
14.4.5.1
MISSION-LED GENOMICS INVESTMENT STRENGTHENS CLINICAL TRANSLATION AND DATA INTEGRATION
 
 
 
 
 
14.4.6
REST OF ASIA PACIFIC
 
 
 
 
 
14.5
LATIN AMERICA
 
 
 
 
 
 
 
14.5.1
BRAZIL
 
 
 
 
 
 
 
14.5.1.1
GROWING GENOMICS INFRASTRUCTURE AND INCREASING PRECISION MEDICINE ADOPTION DRIVE MARKET GROWTH
 
 
 
 
 
14.5.2
REST OF LATIN AMERICA
 
 
 
 
 
14.6
MIDDLE EAST
 
 
 
 
 
 
 
14.6.1
GCC COUNTRIES
 
 
 
 
 
 
 
14.6.1.1
SAUDI ARABIA
 
 
 
 
 
 
 
 
14.6.1.1.1
RISING HEALTHCARE EXPENDITURE, EXPANDING GENOMICS RESEARCH, AND INVESTMENTS IN PRECISION MEDICINE TO PROPEL MARKET
 
 
 
 
14.6.1.2
UAE
 
 
 
 
 
 
 
 
14.6.1.2.1
LARGE-SCALE CITIZEN SEQUENCING MOVES GENOMICS TOWARD PREVENTIVE AND PERSONALIZED CARE
 
 
 
 
14.6.1.3
REST OF GCC COUNTRIES
 
 
 
 
 
14.6.2
REST OF MIDDLE EAST
 
 
 
 
 
14.7
AFRICA
 
 
 
 
 
 
 
14.7.1
DESPITE EMERGING OPPORTUNITIES, GROWTH REMAINS SLOW DUE TO LIMITED ACCESS TO ADVANCED TECHNOLOGY AND INADEQUATE FUNDING & WORKFORCE
 
 
 
 
15
COMPETITIVE LANDSCAPE
Discover strategic maneuvers shaping market dominance and emerging leaders in the multiomics landscape.
 
 
 
 
 
451
 
15.1
OVERVIEW
 
 
 
 
 
 
15.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
 
 
 
 
 
 
 
15.2.1
OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN MULTIOMICS MARKET
 
 
 
 
 
15.3
REVENUE ANALYSIS, 2021–2025
 
 
 
 
 
 
 
15.4
MARKET SHARE ANALYSIS, 2025
 
 
 
 
 
 
 
15.5
COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
 
 
 
 
 
 
 
 
15.5.1
STARS
 
 
 
 
 
 
15.5.2
EMERGING LEADERS
 
 
 
 
 
 
15.5.3
PERVASIVE PLAYERS
 
 
 
 
 
 
15.5.4
PARTICIPANTS
 
 
 
 
 
 
15.5.5
COMPANY FOOTPRINT: KEY PLAYERS, 2025
 
 
 
 
 
 
 
15.5.5.1
COMPANY FOOTPRINT
 
 
 
 
 
 
15.5.5.2
REGION FOOTPRINT
 
 
 
 
 
 
15.5.5.3
OFFERING FOOTPRINT
 
 
 
 
 
 
15.5.5.4
TECHNOLOGY FOOTPRINT
 
 
 
 
 
 
15.5.5.5
WORKFLOW FOOTPRINT
 
 
 
 
15.6
COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
 
 
 
 
 
 
 
 
15.6.1
PROGRESSIVE COMPANIES
 
 
 
 
 
 
15.6.2
RESPONSIVE COMPANIES
 
 
 
 
 
 
15.6.3
DYNAMIC COMPANIES
 
 
 
 
 
 
15.6.4
STARTING BLOCKS
 
 
 
 
 
 
15.6.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
 
 
 
 
 
 
 
15.6.5.1
DETAILED LIST OF KEY STARTUPS/SMES
 
 
 
 
 
 
15.6.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
 
 
 
 
15.7
COMPANY VALUATION AND FINANCIAL METRICS
 
 
 
 
 
 
 
15.7.1
COMPANY VALUATION
 
 
 
 
 
 
15.7.2
FINANCIAL METRICS
 
 
 
 
 
15.8
BRAND/PRODUCT COMPARISON
 
 
 
 
 
 
 
15.9
COMPETITIVE SCENARIO
 
 
 
 
 
 
 
15.9.1
PRODUCT & SERVICE LAUNCHES
 
 
 
 
 
 
15.9.2
DEALS
 
 
 
 
 
 
15.9.3
EXPANSIONS
 
 
 
 
16
COMPANY PROFILES
In-depth Company Profiles of Leading Market Players with detailed Business Overview, Product and Service Portfolio, Recent Developments, and Unique Analyst Perspective (MnM View)
 
 
 
 
 
470
 
16.1
KEY COMPANIES
 
 
 
 
 
 
 
16.1.1
10X GENOMICS
 
 
 
 
 
 
 
16.1.1.1
BUSINESS OVERVIEW
 
 
 
 
 
 
16.1.1.2
PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
16.1.1.3
RECENT DEVELOPMENTS
 
 
 
 
 
 
 
 
16.1.1.3.1
PRODUCT & SERVICE LAUNCHES
 
 
 
 
 
 
16.1.1.3.2
DEALS
 
 
 
 
16.1.1.4
MNM VIEW
 
 
 
 
 
 
 
 
16.1.1.4.1
KEY STRENGTHS
 
 
 
 
 
 
16.1.1.4.2
STRATEGIC CHOICES
 
 
 
 
 
 
16.1.1.4.3
WEAKNESSES AND COMPETITIVE THREATS
 
 
 
16.1.2
THERMO FISHER SCIENTIFIC INC.
 
 
 
 
 
 
16.1.3
ILLUMINA, INC.
 
 
 
 
 
 
16.1.4
OXFORD NANOPORE TECHNOLOGIES PLC
 
 
 
 
 
 
16.1.5
BRUKER
 
 
 
 
 
 
16.1.6
PACBIO
 
 
 
 
 
 
16.1.7
DANAHER CORPORATION
 
 
 
 
 
 
16.1.8
VIZGEN, INC.
 
 
 
 
 
 
16.1.9
AGILENT TECHNOLOGIES, INC.
 
 
 
 
 
 
16.1.10
BIOGNOSYS
 
 
 
 
 
 
16.1.11
MERCK KGAA
 
 
 
 
 
 
16.1.12
QIAGEN N.V.
 
 
 
 
 
 
16.1.13
REVVITY, INC.
 
 
 
 
 
 
16.1.14
WATERS CORPORATION
 
 
 
 
 
 
16.1.15
BIO-RAD LABORATORIES, INC.
 
 
 
 
 
 
16.1.16
TAKARA BIO INC.
 
 
 
 
 
 
16.1.17
METABOLON, INC.
 
 
 
 
 
16.2
OTHER PLAYERS
 
 
 
 
 
 
 
16.2.1
BGI GENOMICS CO., LTD.
 
 
 
 
 
 
16.2.2
NOVOGENE CO., LTD.
 
 
 
 
 
 
16.2.3
AZENTA, INC.
 
 
 
 
 
 
16.2.4
EVOTEC SE
 
 
 
 
 
 
16.2.5
MEDGENOME LABS LTD.
 
 
 
 
 
 
16.2.6
CD GENOMICS
 
 
 
 
 
 
16.2.7
BIOGENITY
 
 
 
 
 
 
16.2.8
SAPIENT BIOANALYTICS, LLC
 
 
 
 
 
 
16.2.9
RAYBIOTECH, INC.
 
 
 
 
 
 
16.2.10
SOURCE BIOSCIENCE LTD.
 
 
 
 
17
RESEARCH METHODOLOGY
 
 
 
 
 
556
 
17.1
RESEARCH DATA
 
 
 
 
 
 
 
17.1.1
SECONDARY DATA
 
 
 
 
 
 
17.1.2
PRIMARY DATA
 
 
 
 
 
17.2
MARKET ESTIMATION METHODOLOGY
 
 
 
 
 
 
 
17.2.1
MARKET SIZE ESTIMATION
 
 
 
 
 
 
17.2.2
INSIGHTS OF PRIMARY EXPERTS
 
 
 
 
 
 
17.2.3
TOP-DOWN APPROACH
 
 
 
 
 
17.3
MARKET GROWTH RATE PROJECTIONS
 
 
 
 
 
 
17.4
MARKET BREAKDOWN AND DATA TRIANGULATION
 
 
 
 
 
 
17.5
RESEARCH ASSUMPTIONS
 
 
 
 
 
 
17.6
RESEARCH LIMITATIONS
 
 
 
 
 
 
17.7
RISK ANALYSIS
 
 
 
 
 
18
APPENDIX
 
 
 
 
 
568
 
18.1
DISCUSSION GUIDE
 
 
 
 
 
 
18.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
 
 
 
 
 
 
18.3
CUSTOMIZATION OPTIONS
 
 
 
 
 
 
18.4
RELATED REPORTS
 
 
 
 
 
 
18.5
AUTHOR DETAILS
 
 
 
 
 
LIST OF TABLES
 
 
 
 
 
 
 
TABLE 1
MULTIOMICS MARKET: IMPACT ANALYSIS
 
 
 
 
 
 
TABLE 2
MULTIOMICS MARKET: PORTER’S FIVE FORCES ANALYSIS
 
 
 
 
 
 
TABLE 3
MULTIOMICS MARKET: ROLE IN ECOSYSTEM
 
 
 
 
 
 
TABLE 4
AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY TYPE, 2023–2025 (USD)
 
 
 
 
 
 
TABLE 5
AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY TYPE, 2023–2025 (USD)
 
 
 
 
 
 
TABLE 6
AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION, 2023–2025 (USD)
 
 
 
 
 
 
TABLE 7
AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY REGION, 2023–2025 (USD)
 
 
 
 
 
 
TABLE 8
IMPORT DATA FOR HS CODE 9027, 2021–2025, (USD THOUSAND)
 
 
 
 
 
 
TABLE 9
EXPORT DATA HS CODE 9027, 2021–2025 (USD THOUSAND)
 
 
 
 
 
 
TABLE 10
IMPORT VOLUME HS CODE 9027, 2021–2025 (TONS)
 
 
 
 
 
 
TABLE 11
EXPORT VOLUME HS CODE 9027, 2021–2025 (TONS)
 
 
 
 
 
 
TABLE 12
MULTIOMICS MARKET: KEY CONFERENCES & EVENTS, 2026–2027
 
 
 
 
 
 
TABLE 13
US-ADJUSTED RECIPROCAL TARIFF RATES
 
 
 
 
 
 
TABLE 14
INDICATIVE LIST OF PATENTS IN MULTIOMICS MARKET, 2025–2026
 
 
 
 
 
 
TABLE 15
CASE STUDIES OF AI IMPLEMENTATION IN MULTIOMICS MARKET
 
 
 
 
 
 
TABLE 16
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN MULTIOMICS MARKET
 
 
 
 
 
 
TABLE 17
NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 18
EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 19
ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 20
REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
 
 
 
 
 
 
TABLE 21
MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 22
MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 23
MULTIOMICS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 24
NORTH AMERICA: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 25
EUROPE: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 26
ASIA PACIFIC: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 27
LATIN AMERICA: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 28
MIDDLE EAST: MULTIOMICS PRODUCTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 29
GCC COUNTRIES: MULTIOMICS PRODUCTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 30
MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 31
MULTIOMICS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 32
NORTH AMERICA: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 33
EUROPE: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 34
ASIA PACIFIC: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 35
LATIN AMERICA: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 36
MIDDLE EAST: MULTIOMICS CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 37
GCC COUNTRIES: MULTIOMICS CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 38
ASSAY KITS & REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 39
NORTH AMERICA: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 40
EUROPE: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 41
ASIA PACIFIC: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 42
LATIN AMERICA: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 43
MIDDLE EAST: ASSAY KITS & REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 44
GCC COUNTRIES: ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 45
OTHER CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 46
NORTH AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 47
EUROPE: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 48
ASIA PACIFIC: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 49
LATIN AMERICA: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 50
MIDDLE EAST: OTHER CONSUMABLES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 51
GCC COUNTRIES: OTHER CONSUMABLES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 52
MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 53
NORTH AMERICA: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 54
EUROPE: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 55
ASIA PACIFIC: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 56
LATIN AMERICA: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 57
MIDDLE EAST: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 58
GCC COUNTRIES: MULTIOMICS INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 59
MULTIOMICS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 60
NORTH AMERICA: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 61
EUROPE: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 62
ASIA PACIFIC: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 63
LATIN AMERICA: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 64
MIDDLE EAST: MULTIOMICS SERVICES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 65
GCC COUNTRIES: MULTIOMICS SERVICES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 66
MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 67
SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 68
SEQUENCING MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 69
NORTH AMERICA: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 70
EUROPE: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 71
ASIA PACIFIC: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 72
LATIN AMERICA: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 73
MIDDLE EAST: SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 74
GCC COUNTRIES: SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 75
LONG-READ SEQUENCING TECHNOLOGY MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 76
LONG-READ SEQUENCING TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 77
NORTH AMERICA: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 78
EUROPE: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 79
ASIA PACIFIC: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 80
LATIN AMERICA: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 81
MIDDLE EAST: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 82
GCC COUNTRIES: LONG-READ SEQUENCING TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 83
NANOPORE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 84
NORTH AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 85
EUROPE: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 86
ASIA PACIFIC: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 87
LATIN AMERICA: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 88
MIDDLE EAST: NANOPORE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 89
GCC COUNTRIES: NANOPORE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 90
SMRT SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 91
NORTH AMERICA: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 92
EUROPE: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 93
ASIA PACIFIC: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 94
LATIN AMERICA: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 95
MIDDLE EAST: SMRT SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 96
GCC COUNTRIES: SMRT SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 97
OTHER SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 98
NORTH AMERICA: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 99
EUROPE: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 100
ASIA PACIFIC: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 101
LATIN AMERICA: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 102
MIDDLE EAST: OTHER SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 103
GCC COUNTRIES: OTHER SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 104
PROTEOMICS TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 105
NORTH AMERICA: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 106
EUROPE: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 107
ASIA PACIFIC: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 108
LATIN AMERICA: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 109
MIDDLE EAST: PROTEOMICS TECHNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 110
GCC COUNTRIES: PROTEOMICS TECHNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 111
OTHER TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 112
NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 113
EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 114
ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 115
LATIN AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 116
MIDDLE EAST: OTHER TECHNOLOGIES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 117
GCC COUNTRIES: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 118
MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 119
SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 120
SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 121
NORTH AMERICA: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 122
EUROPE: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 123
ASIA PACIFIC: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 124
LATIN AMERICA: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 125
MIDDLE EAST: SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 126
GCC COUNTRIES: SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 127
SINGLE-CELL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 128
NORTH AMERICA: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 129
EUROPE: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 130
ASIA PACIFIC: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 131
LATIN AMERICA: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 132
MIDDLE EAST: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 133
GCC COUNTRIES: SINGLE-CELL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 134
SINGLE-CELL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 135
NORTH AMERICA: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 136
EUROPE: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 137
ASIA PACIFIC: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 138
LATIN AMERICA: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 139
MIDDLE EAST: SINGLE-CELL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 140
GCC COUNTRIES: SINGLE-CELL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 141
SINGLE-CELL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 142
NORTH AMERICA: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 143
EUROPE: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 144
ASIA PACIFIC: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 145
LATIN AMERICA: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 146
MIDDLE EAST: SINGLE-CELL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 147
GCC COUNTRIES: SINGLE-CELL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 148
SINGLE-CELL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 149
NORTH AMERICA: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 150
EUROPE: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 151
ASIA PACIFIC: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 152
LATIN AMERICA: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 153
MIDDLE EAST: SINGLE-CELL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 154
GCC COUNTRIES: SINGLE-CELL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 155
OTHER SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 156
NORTH AMERICA: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 157
EUROPE: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 158
ASIA PACIFIC: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 159
LATIN AMERICA: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 160
MIDDLE EAST: OTHER SINGLE-CELL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 161
GCC COUNTRIES: OTHER SINGLE-CELL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 162
PROTEOMICS METHOD MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 163
PROTEOMICS METHOD MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 164
NORTH AMERICA: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 165
EUROPE: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 166
ASIA PACIFIC: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 167
LATIN AMERICA: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 168
MIDDLE EAST: PROTEOMICS METHOD MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 169
GCC COUNTRIES: PROTEOMICS METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 170
MS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 171
NORTH AMERICA: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 172
EUROPE: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 173
ASIA PACIFIC: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 174
LATIN AMERICA: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 175
MIDDLE EAST: MS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 176
GCC COUNTRIES: MS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 177
NGS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 178
NORTH AMERICA: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 179
EUROPE: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 180
ASIA PACIFIC: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 181
LATIN AMERICA: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 182
MIDDLE EAST: NGS-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 183
GCC COUNTRIES: NGS-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 184
PCR-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 185
NORTH AMERICA: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 186
EUROPE: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 187
ASIA PACIFIC: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 188
LATIN AMERICA: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 189
MIDDLE EAST: PCR-BASED PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 190
GCC COUNTRIES: PCR-BASED PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 191
OTHER PROTEOMICS METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 192
NORTH AMERICA: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 193
EUROPE: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 194
ASIA PACIFIC: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 195
LATIN AMERICA: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 196
MIDDLE EAST: OTHER PROTEOMICS METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 197
GCC COUNTRIES: OTHER PROTEOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 198
SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 199
SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 200
NORTH AMERICA: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 201
EUROPE: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 202
ASIA PACIFIC: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 203
LATIN AMERICA: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 204
MIDDLE EAST: SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 205
GCC COUNTRIES: SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 206
SPATIAL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 207
NORTH AMERICA: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 208
EUROPE: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 209
ASIA PACIFIC: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 210
LATIN AMERICA: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 211
MIDDLE EAST: SPATIAL TRANSCRIPTOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 212
GCC COUNTRIES: SPATIAL TRANSCRIPTOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 213
SPATIAL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 214
NORTH AMERICA: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 215
EUROPE: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 216
ASIA PACIFIC: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 217
LATIN AMERICA: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 218
MIDDLE EAST: SPATIAL PROTEOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 219
GCC COUNTRIES: SPATIAL PROTEOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 220
SPATIAL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 221
NORTH AMERICA: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 222
EUROPE: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 223
ASIA PACIFIC: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 224
LATIN AMERICA: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 225
MIDDLE EAST: SPATIAL EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 226
GCC COUNTRIES: SPATIAL EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 227
SPATIAL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 228
NORTH AMERICA: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 229
EUROPE: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 230
ASIA PACIFIC: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 231
LATIN AMERICA: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 232
MIDDLE EAST: SPATIAL GENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 233
GCC COUNTRIES: SPATIAL GENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 234
OTHER SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 235
NORTH AMERICA: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 236
EUROPE: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 237
ASIA PACIFIC: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 238
LATIN AMERICA: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 239
MIDDLE EAST: OTHER SPATIAL OMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 240
GCC COUNTRIES: OTHER SPATIAL OMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 241
LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 242
LONG-READ & LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 243
NORTH AMERICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 244
EUROPE: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 245
ASIA PACIFIC: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 246
LATIN AMERICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 247
MIDDLE EAST: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 248
GCC COUNTRIES: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 249
LONG-READ SEQUENCING METHOD MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 250
NORTH AMERICA: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 251
EUROPE: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 252
ASIA PACIFIC: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 253
LATIN AMERICA: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 254
MIDDLE EAST: LONG-READ SEQUENCING METHOD MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 255
GCC COUNTRIES: LONG-READ SEQUENCING METHOD MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 256
LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 257
NORTH AMERICA: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 258
EUROPE: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 259
ASIA PACIFIC: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 260
LATIN AMERICA: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 261
MIDDLE EAST: LONG-RANGE SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 262
GCC COUNTRIES: LONG-RANGE SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 263
OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 264
NORTH AMERICA: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 265
EUROPE: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 266
ASIA PACIFIC: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 267
LATIN AMERICA: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 268
MIDDLE EAST: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 269
GCC COUNTRIES: OTHER LONG-READ & LONG-RANGE SEQUENCING METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 270
EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 271
EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 272
NORTH AMERICA: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 273
EUROPE: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 274
ASIA PACIFIC: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 275
LATIN AMERICA: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 276
MIDDLE EAST: EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 277
GCC COUNTRIES: EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 278
SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 279
SEQUENCING-BASED EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 280
NORTH AMERICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 281
EUROPE: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 282
ASIA PACIFIC: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 283
LATIN AMERICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 284
MIDDLE EAST: SEQUENCING-BASED EPIGENOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 285
GCC COUNTRIES: SEQUENCING-BASED EPIGENOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 286
DNA METHYLATION SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 287
NORTH AMERICA: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 288
EUROPE: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 289
ASIA PACIFIC: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 290
LATIN AMERICA: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 291
MIDDLE EAST: DNA METHYLATION SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 292
GCC COUNTRIES: DNA METHYLATION SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 293
CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 294
NORTH AMERICA: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 295
EUROPE: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 296
ASIA PACIFIC: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 297
LATIN AMERICA: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 298
MIDDLE EAST: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 299
GCC COUNTRIES: CHROMATIN ACCESSIBILITY SEQUENCING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 300
HISTONE MODIFICATION PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 301
NORTH AMERICA: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 302
EUROPE: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 303
ASIA PACIFIC: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 304
LATIN AMERICA: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 305
MIDDLE EAST: HISTONE MODIFICATION PROFILING MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 306
GCC COUNTRIES: HISTONE MODIFICATION PROFILING MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 307
CHROMATIN INTERACTION ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 308
NORTH AMERICA: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 309
EUROPE: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 310
ASIA PACIFIC: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 311
LATIN AMERICA: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 312
MIDDLE EAST: CHROMATIN INTERACTION ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 313
GCC COUNTRIES: CHROMATIN INTERACTION ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 314
OTHER EPIGENOMICS METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 315
NORTH AMERICA: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 316
EUROPE: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 317
ASIA PACIFIC: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 318
LATIN AMERICA: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 319
MIDDLE EAST: OTHER EPIGENOMICS METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 320
GCC COUNTRIES: OTHER EPIGENOMICS METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 321
OTHER METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 322
NORTH AMERICA: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 323
EUROPE: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 324
ASIA PACIFIC: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 325
LATIN AMERICA: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 326
MIDDLE EAST: OTHER METHODS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 327
GCC COUNTRIES: OTHER METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 328
MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 329
SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 330
NORTH AMERICA: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 331
EUROPE: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 332
ASIA PACIFIC: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 333
LATIN AMERICA: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 334
MIDDLE EAST: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 335
GCC COUNTRIES: SEQUENCING & ANALYSIS/SAMPLE CHARACTERIZATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 336
SAMPLE PREPARATION MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 337
NORTH AMERICA: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 338
EUROPE: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 339
ASIA PACIFIC: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 340
LATIN AMERICA: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 341
MIDDLE EAST: SAMPLE PREPARATION MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 342
GCC COUNTRIES: SAMPLE PREPARATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 343
DATA VISUALIZATION & ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 344
NORTH AMERICA: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 345
EUROPE: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 346
ASIA PACIFIC: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 347
LATIN AMERICA: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 348
MIDDLE EAST: DATA VISUALIZATION & ANALYSIS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 349
GCC COUNTRIES: DATA VISUALIZATION & ANALYSIS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 350
MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 351
ONCOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 352
NORTH AMERICA: ONCOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 353
EUROPE: ONCOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 354
ASIA PACIFIC: ONCOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 355
LATIN AMERICA: ONCOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 356
MIDDLE EAST: ONCOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 357
GCC COUNTRIES: ONCOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 358
DRUG DISCOVERY & DEVELOPMENT MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 359
NORTH AMERICA: DRUG DISCOVERY & DEVELOPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 360
EUROPE: DRUG DISCOVERY & DEVELOPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 361
ASIA PACIFIC: DRUG DISCOVERY & DEVELOPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 362
LATIN AMERICA: DRUG DISCOVERY & DEVELOPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 363
MIDDLE EAST: DRUG DISCOVERY & DEVELOPMENT MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 364
GCC COUNTRIES: DRUG DISCOVERY & DEVELOPMENT MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 365
IMMUNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 366
NORTH AMERICA: IMMUNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 367
EUROPE: IMMUNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 368
ASIA PACIFIC: IMMUNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 369
LATIN AMERICA: IMMUNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 370
MIDDLE EAST: IMMUNOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 371
GCC COUNTRIES: IMMUNOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 372
PRECISION MEDICINE MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 373
NORTH AMERICA: PRECISION MEDICINE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 374
EUROPE: PRECISION MEDICINE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 375
ASIA PACIFIC: PRECISION MEDICINE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 376
LATIN AMERICA: PRECISION MEDICINE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 377
MIDDLE EAST: PRECISION MEDICINE MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 378
GCC COUNTRIES: PRECISION MEDICINE MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 379
BIOMARKER DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 380
NORTH AMERICA: BIOMARKER DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 381
EUROPE: BIOMARKER DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 382
ASIA PACIFIC: BIOMARKER DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 383
LATIN AMERICA: BIOMARKER DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 384
MIDDLE EAST: BIOMARKER DISCOVERY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 385
GCC COUNTRIES: BIOMARKER DISCOVERY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 386
CELL BIOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 387
NORTH AMERICA: CELL BIOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 388
EUROPE: CELL BIOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 389
ASIA PACIFIC: CELL BIOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 390
LATIN AMERICA: CELL BIOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 391
MIDDLE EAST: CELL BIOLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 392
GCC COUNTRIES: CELL BIOLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 393
TRANSLATIONAL RESEARCH MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 394
NORTH AMERICA: TRANSLATIONAL RESEARCH MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 395
EUROPE: TRANSLATIONAL RESEARCH MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 396
ASIA PACIFIC: TRANSLATIONAL RESEARCH MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 397
LATIN AMERICA: TRANSLATIONAL RESEARCH MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 398
MIDDLE EAST: TRANSLATIONAL RESEARCH MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 399
GCC COUNTRIES: TRANSLATIONAL RESEARCH MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 400
NEUROLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 401
NORTH AMERICA: NEUROLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 402
EUROPE: NEUROLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 403
ASIA PACIFIC: NEUROLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 404
LATIN AMERICA: NEUROLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 405
MIDDLE EAST: NEUROLOGY MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 406
GCC COUNTRIES: NEUROLOGY MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 407
CLINICAL DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 408
NORTH AMERICA: CLINICAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 409
EUROPE: CLINICAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 410
ASIA PACIFIC: CLINICAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 411
LATIN AMERICA: CLINICAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 412
MIDDLE EAST: CLINICAL DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 413
GCC COUNTRIES: CLINICAL DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 414
OTHER APPLICATIONS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 415
NORTH AMERICA: OTHER APPLICATIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 416
EUROPE: OTHER APPLICATIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 417
ASIA PACIFIC: OTHER APPLICATIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 418
LATIN AMERICA: OTHER APPLICATIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 419
MIDDLE EAST: OTHER APPLICATIONS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 420
GCC COUNTRIES: OTHER APPLICATIONS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 421
MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 422
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 423
NORTH AMERICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 424
EUROPE: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 425
ASIA PACIFIC: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 426
LATIN AMERICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 427
MIDDLE EAST: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 428
GCC COUNTRIES: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 429
ACADEMIC & RESEARCH INSTITUTES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 430
NORTH AMERICA: ACADEMIC & RESEARCH INSTITUTES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 431
EUROPE: ACADEMIC & RESEARCH INSTITUTES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 432
ASIA PACIFIC: ACADEMIC & RESEARCH INSTITUTES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 433
LATIN AMERICA: ACADEMIC & RESEARCH INSTITUTES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 434
MIDDLE EAST: ACADEMIC & RESEARCH INSTITUTES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 435
GCC COUNTRIES: ACADEMIC & RESEARCH INSTITUTES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 436
CROS & CDMOS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 437
NORTH AMERICA: CROS & CDMOS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 438
EUROPE: CROS & CDMOS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 439
ASIA PACIFIC: CROS & CDMOS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 440
LATIN AMERICA: CROS & CDMOS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 441
MIDDLE EAST: CROS & CDMOS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 442
GCC COUNTRIES: CROS & CDMOS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 443
HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 444
NORTH AMERICA: HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 445
EUROPE: HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 446
ASIA PACIFIC: HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 447
LATIN AMERICA: HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 448
MIDDLE EAST: HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 449
GCC COUNTRIES: HOSPITALS & DIAGNOSTIC/CLINICAL LABORATORIES MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 450
MULTIOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 451
NORTH AMERICA: MULTIOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 452
NORTH AMERICA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 453
NORTH AMERICA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 454
NORTH AMERICA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 455
NORTH AMERICA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 456
NORTH AMERICA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 457
NORTH AMERICA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 458
NORTH AMERICA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 459
NORTH AMERICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 460
NORTH AMERICA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 461
NORTH AMERICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 462
NORTH AMERICA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 463
NORTH AMERICA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 464
NORTH AMERICA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 465
NORTH AMERICA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 466
NORTH AMERICA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 467
NORTH AMERICA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 468
US: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 469
US: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 470
US: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 471
US: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 472
US: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 473
US: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 474
US: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 475
US: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 476
US: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 477
US: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 478
US: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 479
US: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 480
US: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 481
US: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 482
US: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 483
US: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 484
CANADA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 485
CANADA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 486
CANADA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 487
CANADA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 488
CANADA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 489
CANADA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 490
CANADA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 491
CANADA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 492
CANADA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 493
CANADA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 494
CANADA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 495
CANADA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 496
CANADA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 497
CANADA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 498
CANADA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 499
CANADA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 500
EUROPE: MULTIOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 501
EUROPE: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 502
EUROPE: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 503
EUROPE: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 504
EUROPE: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 505
EUROPE: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 506
EUROPE: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 507
EUROPE: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 508
EUROPE: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 509
EUROPE: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 510
EUROPE: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 511
EUROPE: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 512
EUROPE: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 513
EUROPE: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 514
EUROPE: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 515
EUROPE: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 516
EUROPE: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 517
GERMANY: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 518
GERMANY: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 519
GERMANY: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 520
GERMANY: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 521
GERMANY: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 522
GERMANY: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 523
GERMANY: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 524
GERMANY: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 525
GERMANY: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 526
GERMANY: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 527
GERMANY: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 528
GERMANY: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 529
GERMANY: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 530
GERMANY: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 531
GERMANY: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 532
GERMANY: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 533
UK: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 534
UK: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 535
UK: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 536
UK: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 537
UK: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 538
UK: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 539
UK: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 540
UK: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 541
UK: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 542
UK: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 543
UK: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 544
UK: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 545
UK: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 546
UK: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 547
UK: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 548
UK: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 549
FRANCE: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 550
FRANCE: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 551
FRANCE: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 552
FRANCE: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 553
FRANCE: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 554
FRANCE: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 555
FRANCE: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 556
FRANCE: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 557
FRANCE: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 558
FRANCE: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 559
FRANCE: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 560
FRANCE: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 561
FRANCE: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 562
FRANCE: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 563
FRANCE: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 564
FRANCE: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 565
ITALY: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 566
ITALY: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 567
ITALY: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 568
ITALY: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 569
ITALY: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 570
ITALY: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 571
ITALY: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 572
ITALY: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 573
ITALY: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 574
ITALY: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 575
ITALY: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 576
ITALY: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 577
ITALY: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 578
ITALY: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 579
ITALY: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 580
ITALY: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 581
SPAIN: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 582
SPAIN: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 583
SPAIN: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 584
SPAIN: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 585
SPAIN: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 586
SPAIN: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 587
SPAIN: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 588
SPAIN: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 589
SPAIN: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 590
SPAIN: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 591
SPAIN: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 592
SPAIN: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 593
SPAIN: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 594
SPAIN: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 595
SPAIN: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 596
SPAIN: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 597
REST OF EUROPE: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 598
REST OF EUROPE: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 599
REST OF EUROPE: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 600
REST OF EUROPE: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 601
REST OF EUROPE: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 602
REST OF EUROPE: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 603
REST OF EUROPE: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 604
REST OF EUROPE: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 605
REST OF EUROPE: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 606
REST OF EUROPE: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 607
REST OF EUROPE: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 608
REST OF EUROPE: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 609
REST OF EUROPE: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 610
REST OF EUROPE: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 611
REST OF EUROPE: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 612
REST OF EUROPE: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 613
ASIA PACIFIC: MULTIOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 614
ASIA PACIFIC: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 615
ASIA PACIFIC: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 616
ASIA PACIFIC: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 617
ASIA PACIFIC: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 618
ASIA PACIFIC: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 619
ASIA PACIFIC: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 620
ASIA PACIFIC: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 621
ASIA PACIFIC: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 622
ASIA PACIFIC: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 623
ASIA PACIFIC: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 624
ASIA PACIFIC: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 625
ASIA PACIFIC: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 626
ASIA PACIFIC: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 627
ASIA PACIFIC: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 628
ASIA PACIFIC: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 629
ASIA PACIFIC: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 630
CHINA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 631
CHINA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 632
CHINA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 633
CHINA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 634
CHINA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 635
CHINA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 636
CHINA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 637
CHINA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 638
CHINA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 639
CHINA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 640
CHINA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 641
CHINA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 642
CHINA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 643
CHINA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 644
CHINA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 645
CHINA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 646
JAPAN: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 647
JAPAN: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 648
JAPAN: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 649
JAPAN: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 650
JAPAN: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 651
JAPAN: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 652
JAPAN: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 653
JAPAN: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 654
JAPAN: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 655
JAPAN: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 656
JAPAN: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 657
JAPAN: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 658
JAPAN: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 659
JAPAN: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 660
JAPAN: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 661
JAPAN: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 662
SOUTH KOREA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 663
SOUTH KOREA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 664
SOUTH KOREA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 665
SOUTH KOREA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 666
SOUTH KOREA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 667
SOUTH KOREA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 668
SOUTH KOREA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 669
SOUTH KOREA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 670
SOUTH KOREA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 671
SOUTH KOREA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 672
SOUTH KOREA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 673
SOUTH KOREA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 674
SOUTH KOREA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 675
SOUTH KOREA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 676
SOUTH KOREA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 677
SOUTH KOREA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 678
INDIA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 679
INDIA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 680
INDIA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 681
INDIA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 682
INDIA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 683
INDIA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 684
INDIA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 685
INDIA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 686
INDIA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 687
INDIA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 688
INDIA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 689
INDIA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 690
INDIA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 691
INDIA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 692
INDIA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 693
INDIA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 694
AUSTRALIA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 695
AUSTRALIA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 696
AUSTRALIA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 697
AUSTRALIA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 698
AUSTRALIA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 699
AUSTRALIA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 700
AUSTRALIA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 701
AUSTRALIA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 702
AUSTRALIA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 703
AUSTRALIA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 704
AUSTRALIA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 705
AUSTRALIA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 706
AUSTRALIA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 707
AUSTRALIA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 708
AUSTRALIA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 709
AUSTRALIA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 710
REST OF ASIA PACIFIC: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 711
REST OF ASIA PACIFIC: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 712
REST OF ASIA PACIFIC: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 713
REST OF ASIA PACIFIC: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 714
REST OF ASIA PACIFIC: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 715
REST OF ASIA PACIFIC: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 716
REST OF ASIA PACIFIC: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 717
REST OF ASIA PACIFIC: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 718
REST OF ASIA PACIFIC: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 719
REST OF ASIA PACIFIC: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 720
REST OF ASIA PACIFIC: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 721
REST OF ASIA PACIFIC: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 722
REST OF ASIA PACIFIC: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 723
REST OF ASIA PACIFIC: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 724
REST OF ASIA PACIFIC: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 725
REST OF ASIA PACIFIC: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 726
LATIN AMERICA: MULTIOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 727
LATIN AMERICA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 728
LATIN AMERICA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 729
LATIN AMERICA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 730
LATIN AMERICA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 731
LATIN AMERICA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 732
LATIN AMERICA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 733
LATIN AMERICA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 734
LATIN AMERICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 735
LATIN AMERICA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 736
LATIN AMERICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 737
LATIN AMERICA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 738
LATIN AMERICA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 739
LATIN AMERICA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 740
LATIN AMERICA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 741
LATIN AMERICA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 742
LATIN AMERICA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 743
BRAZIL: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 744
BRAZIL: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 745
BRAZIL: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 746
BRAZIL: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 747
BRAZIL: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 748
BRAZIL: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 749
BRAZIL: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 750
BRAZIL: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 751
BRAZIL: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 752
BRAZIL: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 753
BRAZIL: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 754
BRAZIL: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 755
BRAZIL: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 756
BRAZIL: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 757
BRAZIL: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 758
BRAZIL: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 759
REST OF LATIN AMERICA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 760
REST OF LATIN AMERICA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 761
REST OF LATIN AMERICA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 762
REST OF LATIN AMERICA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 763
REST OF LATIN AMERICA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 764
REST OF LATIN AMERICA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 765
REST OF LATIN AMERICA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 766
REST OF LATIN AMERICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 767
REST OF LATIN AMERICA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 768
REST OF LATIN AMERICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 769
REST OF LATIN AMERICA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 770
REST OF LATIN AMERICA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 771
REST OF LATIN AMERICA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 772
REST OF LATIN AMERICA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 773
REST OF LATIN AMERICA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 774
REST OF LATIN AMERICA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 775
MIDDLE EAST: MULTIOMICS MARKET, BY REGION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 776
MIDDLE EAST: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 777
MIDDLE EAST: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 778
MIDDLE EAST: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 779
MIDDLE EAST: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 780
MIDDLE EAST: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 781
MIDDLE EAST: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 782
MIDDLE EAST: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 783
MIDDLE EAST: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 784
MIDDLE EAST: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 785
MIDDLE EAST: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 786
MIDDLE EAST: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 787
MIDDLE EAST: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 788
MIDDLE EAST: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 789
MIDDLE EAST: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 790
MIDDLE EAST: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 791
MIDDLE EAST: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 792
GCC COUNTRIES: MULTIOMICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 793
GCC COUNTRIES: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 794
GCC COUNTRIES: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 795
GCC COUNTRIES: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 796
GCC COUNTRIES: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 797
GCC COUNTRIES: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 798
GCC COUNTRIES: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 799
GCC COUNTRIES: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 800
GCC COUNTRIES: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 801
GCC COUNTRIES: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 802
GCC COUNTRIES: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 803
GCC COUNTRIES: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 804
GCC COUNTRIES: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 805
GCC COUNTRIES: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 806
GCC COUNTRIES: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 807
GCC COUNTRIES: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 808
GCC COUNTRIES: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 809
SAUDI ARABIA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 810
SAUDI ARABIA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 811
SAUDI ARABIA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 812
SAUDI ARABIA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 813
SAUDI ARABIA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 814
SAUDI ARABIA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 815
SAUDI ARABIA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 816
SAUDI ARABIA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 817
SAUDI ARABIA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 818
SAUDI ARABIA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 819
SAUDI ARABIA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 820
SAUDI ARABIA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 821
SAUDI ARABIA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 822
SAUDI ARABIA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 823
SAUDI ARABIA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 824
SAUDI ARABIA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 825
UAE: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 826
UAE: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 827
UAE: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 828
UAE: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 829
UAE: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 830
UAE: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 831
UAE: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 832
UAE: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 833
UAE: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 834
UAE: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 835
UAE: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 836
UAE: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 837
UAE: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 838
UAE: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 839
UAE: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 840
UAE: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 841
REST OF GCC COUNTRIES: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 842
REST OF GCC COUNTRIES: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 843
REST OF GCC COUNTRIES: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 844
REST OF GCC COUNTRIES: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 845
REST OF GCC COUNTRIES: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 846
REST OF GCC COUNTRIES: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 847
REST OF GCC COUNTRIES: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 848
REST OF GCC COUNTRIES: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 849
REST OF GCC COUNTRIES: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 850
REST OF GCC COUNTRIES: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 851
REST OF GCC COUNTRIES: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 852
REST OF GCC COUNTRIES: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 853
REST OF GCC COUNTRIES: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 854
REST OF GCC COUNTRIES: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 855
REST OF GCC COUNTRIES: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 856
REST OF GCC COUNTRIES: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 857
REST OF MIDDLE EAST: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 858
REST OF MIDDLE EAST: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 859
REST OF MIDDLE EAST: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 860
REST OF MIDDLE EAST: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 861
REST OF MIDDLE EAST: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 862
REST OF MIDDLE EAST: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 863
REST OF MIDDLE EAST: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 864
REST OF MIDDLE EAST: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 865
REST OF MIDDLE EAST: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 866
REST OF MIDDLE EAST: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 867
REST OF MIDDLE EAST: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 868
REST OF MIDDLE EAST: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 869
REST OF MIDDLE EAST: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 870
REST OF MIDDLE EAST: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 871
REST OF MIDDLE EAST: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 872
REST OF MIDDLE EAST: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 873
AFRICA: MULTIOMICS MARKET, BY OFFERING, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 874
AFRICA: MULTIOMICS PRODUCTS MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 875
AFRICA: MULTIOMICS CONSUMABLES MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 876
AFRICA: MULTIOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 877
AFRICA: SINGLE-CELL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 878
AFRICA: PROTEOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 879
AFRICA: SPATIAL OMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 880
AFRICA: LONG-READ & LONG-RANGE SEQUENCING MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 881
AFRICA: EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 882
AFRICA: SEQUENCING-BASED EPIGENOMICS MARKET, BY METHOD, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 883
AFRICA: MULTIOMICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 884
AFRICA: SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 885
AFRICA: LONG-READ SEQUENCING MARKET, BY TYPE, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 886
AFRICA: MULTIOMICS MARKET, BY WORKFLOW, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 887
AFRICA: MULTIOMICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 888
AFRICA: MULTIOMICS MARKET, BY END USER, 2024–2031 (USD MILLION)
 
 
 
 
 
 
TABLE 889
OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS
 
 
 
 
 
 
TABLE 890
MULTIOMICS MARKET: DEGREE OF COMPETITION
 
 
 
 
 
 
TABLE 891
MULTIOMICS MARKET: REGION FOOTPRINT
 
 
 
 
 
 
TABLE 892
MULTIOMICS MARKET: OFFERING FOOTPRINT
 
 
 
 
 
 
TABLE 893
MULTIOMICS MARKET: TECHNOLOGY FOOTPRINT
 
 
 
 
 
 
TABLE 894
MULTIOMICS MARKET: WORKFLOW FOOTPRINT
 
 
 
 
 
 
TABLE 895
MULTIOMICS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
 
 
 
 
 
 
TABLE 896
MULTIOMICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
 
 
 
 
 
 
TABLE 897
MULTIOMICS MARKET: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 898
MULTIOMICS MARKET: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 899
MULTIOMICS MARKET: EXPANSIONS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 900
10X GENOMICS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 901
10X GENOMICS: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 902
10X GENOMICS, INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 903
10X GENOMICS, INC.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 904
THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 905
THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 906
THERMO FISHER SCIENTIFIC INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 907
THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 908
ILLUMINA, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 909
ILLUMINA, INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 910
ILLUMINA, INC: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 911
ILLUMINA, INC.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 912
OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 913
OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 914
OXFORD NANOPORE TECHNOLOGIES PLC: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 915
OXFORD NANOPORE TECHNOLOGIES PLC: EXPANSIONS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 916
BRUKER: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 917
BRUKER: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 918
BRUKER : PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 919
BRUKER : DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 920
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 921
PACBIO.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 922
PACBIO.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 923
PACBIO.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 924
DANAHER CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 925
DANAHER CORPORATION: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 926
DANAHER CORPORATION: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 927
DANAHER CORPORATION: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 928
VIZGEN, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 929
VIZGEN, INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 930
VIZGEN, INC.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 931
AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 932
AGILENT TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 933
AGILENT TECHNOLOGIES, INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 934
AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 935
AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 936
BIOGNOSYS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 937
BIOGNOSYS: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 938
BIOGNOSYS: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 939
MERCK KGAA: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 940
MERCK KGAA: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 941
MERCK KGAA: EXPANSIONS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 942
QIAGEN: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 943
QIAGEN: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 944
QIAGEN: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 945
QIAGEN: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 946
QIAGEN: EXPANSIONS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 947
REVVITY: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 948
REVVITY: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 949
REVVITY: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 950
REVVITY: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 951
WATERS CORPORATION: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 952
WATERS CORPORATION: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 953
WATERS CORPORATION: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 954
WATERS CORPORATION: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 955
WATERS CORPORATION: EXPANSIONS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 956
BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 957
BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 958
BIO-RAD LABORATORIES, INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 959
BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 960
TAKARA BIO INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 961
TAKARA BIO INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 962
TAKARA BIO INC.: EXPANSIONS, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 963
METABOLON, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 964
METABOLON, INC.: PRODUCTS & SERVICES OFFERED
 
 
 
 
 
 
TABLE 965
METABOLON, INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–JULY 2026
 
 
 
 
 
 
TABLE 966
BGI GENOMICS CO., LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 967
NOVOGENE CO., LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 968
AZENTA, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 969
EVOTEC SE: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 970
MEDGENOME LABS LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 971
CD GENOMICS: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 972
BIOGENITY: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 973
SAPIENT BIOANALYTICS, LLC: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 974
RAYBIOTECH, INC.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 975
SOURCE BIOSCIENCE LTD.: COMPANY OVERVIEW
 
 
 
 
 
 
TABLE 976
IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
 
 
 
 
 
 
LIST OF FIGURES
 
 
 
 
 
 
 
FIGURE 1
MARKETS COVERED AND REGIONS CONSIDERED
 
 
 
 
 
 
FIGURE 2
MARKET SCENARIO
 
 
 
 
 
 
FIGURE 3
GLOBAL MULTIOMICS MARKET, 2024–2031
 
 
 
 
 
 
FIGURE 4
MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN MULTIOMICS MARKET, 2023–2026
 
 
 
 
 
 
FIGURE 5
DISRUPTIONS INFLUENCING THE GROWTH OF MULTIOMICS MARKET
 
 
 
 
 
 
FIGURE 6
HIGH-GROWTH SEGMENTS IN MULTIOMICS MARKET, 2026–2031
 
 
 
 
 
 
FIGURE 7
ASIA PACIFIC TO REGISTER HIGHEST CAGR IN MULTIOMICS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 8
RAPID ADOPTION OF SINGLE-CELL AND SPATIAL MULTIOMICS TO DRIVE MARKET
 
 
 
 
 
 
FIGURE 9
PRODUCTS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2025
 
 
 
 
 
 
FIGURE 10
INDIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 11
PRODUCTS TO DOMINATE MARKET DURING FORECAST PERIOD
 
 
 
 
 
 
FIGURE 12
MULTIOMICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
 
 
 
 
 
 
FIGURE 13
MULTIOMICS MARKET: PORTERS FIVE FORCES ANALYSIS
 
 
 
 
 
 
FIGURE 14
MULTIOMICS MARKET: VALUE CHAIN ANALYSIS
 
 
 
 
 
 
FIGURE 15
MULTIOMICS MARKET: ECOSYSTEM ANALYSIS
 
 
 
 
 
 
FIGURE 16
AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY TYPE, 2023–2025 (USD)
 
 
 
 
 
 
FIGURE 17
AVERAGE SELLING PRICE OF CONSUMABLES, 2023– 2025 (USD)
 
 
 
 
 
 
FIGURE 18
AVERAGE SELLING PRICE OF INSTRUMENTS, BY REGION, 2025 (USD)
 
 
 
 
 
 
FIGURE 19
AVERAGE SELLING PRICE OF CONSUMABLES, BY REGION, 2025 (USD)
 
 
 
 
 
 
FIGURE 20
MULTIOMICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
 
 
 
 
 
 
FIGURE 21
INVESTMENT/FUNDING ACTIVITY IN MULTIOMICS MARKET
 
 
 
 
 
 
FIGURE 22
TOP APPLICANTS/OWNERS (COMPANIES) FOR MULTIOMICS PATENTS, 2015–2025
 
 
 
 
 
 
FIGURE 23
IMPACT OF AI/GEN AI ON MULTIOMICS MARKET
 
 
 
 
 
 
FIGURE 24
NORTH AMERICA: MULTIOMICS MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 25
ASIA PACIFIC: MULTIOMICS MARKET SNAPSHOT
 
 
 
 
 
 
FIGURE 26
REVENUE ANALYSIS OF KEY PLAYERS, 2021–2025 (USD MILLION)
 
 
 
 
 
 
FIGURE 27
MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025
 
 
 
 
 
 
FIGURE 28
MULTIOMICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
 
 
 
 
 
 
FIGURE 29
MULTIOMICS MARKET: COMPANY FOOTPRINT
 
 
 
 
 
 
FIGURE 30
MULTIOMICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
 
 
 
 
 
 
FIGURE 31
YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 32
EV/EBITDA OF KEY VENDORS
 
 
 
 
 
 
FIGURE 33
MULTIOMICS MARKET: BRAND/PRODUCT COMPARISON
 
 
 
 
 
 
FIGURE 34
10X GENOMICS: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 35
THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 36
ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 37
OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 38
BRUKER: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 39
PACBIO.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 40
DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 41
AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 42
MERCK KGAA: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 43
QIAGEN: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 44
REVVITY: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 45
WATERS CORPORATION: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 46
BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 47
TAKARA BIO INC.: COMPANY SNAPSHOT (2025)
 
 
 
 
 
 
FIGURE 48
RESEARCH DESIGN
 
 
 
 
 
 
FIGURE 49
MULTIOMICS MARKET: BREAKDOWN OF PRIMARIES
 
 
 
 
 
 
FIGURE 50
MULTIOMICS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
 
 
 
 
 
 
FIGURE 51
MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025
 
 
 
 
 
 
FIGURE 52
REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC. (2025)
 
 
 
 
 
 
FIGURE 53
MARKET SIZE VALIDATION FROM PRIMARY SOURCES
 
 
 
 
 
 
FIGURE 54
MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
 
 
 
 
 
 
FIGURE 55
MULTIOMICS MARKET CAGR PROJECTIONS
 
 
 
 
 
 
FIGURE 56
DATA TRIANGULATION METHODOLOGY
 
 
 
 
 
 

Methodology

This study involved four major activities in estimating the current size of the multiomics market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), European Bioinformatics Institute (EMBL-EBI), US Food and Drug Administration (FDA), European Medicines Agency (EMA), World Health Organization (WHO), and Organisation for Economic Co-operation and Development (OECD). Omics-specific repositories and research initiatives, including Human Protein Atlas, the Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), Clinical Proteomic Tumor Analysis Consortium (CPTAC), among several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Multiomics market, and the findings were validated through primary research.

Primary Research

In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Multiomics Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the multiomics market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Multiomics Market : Top-Down and Bottom-Up Approach

Multiomics Market Top Down and Bottom Up Approach

Data Triangulation

After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.

Market Definition

The multiomics market comprises commercial revenues generated from products and services used to perform integrated multiomics analyses by combining two or more molecular profiling modalities, such as genomics, epigenomics, transcriptomics, proteomics, and spatial or single-cell omics. The market includes instruments, software, assay kits, reagents, consumables, and analytical services supporting advanced multiomics workflows from sample preparation and molecular characterization to data integration, visualization, and interpretation. These technologies are used across research and clinical applications, including oncology, precision medicine, biomarker discovery, translational research, drug discovery, and clinical diagnostics, by pharmaceutical and biotechnology companies, academic and research institutions, hospitals, diagnostic laboratories, CROs, and CDMOs. The market excludes conventional single-omics technologies, routine short-read sequencing workflows, microarray-based molecular profiling, and general laboratory products not specifically designed for integrated multiomics applications.

Key Stakeholders

  • Multiomics product & service providers
  • Multiomics bioinformatics/data analysis companies
  • Venture capitalists and other government funding organizations
  • Research and consulting firms
  • Hospitals and diagnostic clinics
  • Pharmaceutical and biotechnology companies
  • Academic and government research institutes
  • Life science companies

Report Objectives

  • To define, describe, and forecast the multiomics market by offering, method, technology, workflow, application, end user, and region
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall multiomics market
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
  • To profile the key players and analyze their market shares and core competencies
  • To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
  • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

Available customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographical Analysis

  • Further breakdown of the Rest of Europe multiomics market, by country
  • Further breakdown of the Rest of Asia Pacific multiomics market, by country

Company Analysis

  • Detailed analysis and profiling of additional market players (up to five)

Segment Analysis

  • Cross-segment analysis

TABLE OF CONTENTS

METHODOLOGY

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
Cite this Research

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Multiomics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

TESTIMONIALS

Growth opportunities and latent adjacency in Multiomics Market

DMCA.com Protection Status
popup img